Business Description
Valerio Therapeutics
ISIN : FR0010095596
Compare
Compare
Traded in other countries / regions
ALVIO.FranceC4X.GermanyONXEO.Denmark0NWK.UK IPO Date
2005-07-12Description
Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.76 | |||||
| Equity-to-Asset | 0.53 | |||||
| Debt-to-Equity | 0.41 | |||||
| Debt-to-EBITDA | -0.49 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -1.05 | |||||
| Beneish M-Score | -5.17 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -39.9 | |||||
| 3-Year EBITDA Growth Rate | -3.1 | |||||
| 3-Year EPS without NRI Growth Rate | 7 | |||||
| 3-Year FCF Growth Rate | 7.3 | |||||
| 3-Year Book Growth Rate | -10.5 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 20.86 | |||||
| 9-Day RSI | 34.39 | |||||
| 14-Day RSI | 41.06 | |||||
| 6-1 Month Momentum % | -41.62 | |||||
| 12-1 Month Momentum % | -62.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.79 | |||||
| Quick Ratio | 1.79 | |||||
| Cash Ratio | 1.39 | |||||
| Days Sales Outstanding | 1189.52 | |||||
| Days Payable | 2974.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -21.8 | |||||
| Shareholder Yield % | -48.76 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 65.97 | |||||
| Operating Margin % | -1397.3 | |||||
| Net Margin % | -1367.64 | |||||
| FCF Margin % | -1221.83 | |||||
| ROE % | -78.58 | |||||
| ROA % | -41.17 | |||||
| ROIC % | -73.28 | |||||
| ROC (Joel Greenblatt) % | -1016.97 | |||||
| ROCE % | -51.7 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 8.46 | |||||
| PB Ratio | 0.73 | |||||
| Price-to-Tangible-Book | 5.4 | |||||
| EV-to-EBIT | -0.48 | |||||
| EV-to-EBITDA | -0.47 | |||||
| EV-to-Revenue | 6.48 | |||||
| EV-to-FCF | -0.55 | |||||
| Price-to-Median-PS-Value | 0.68 | |||||
| Earnings Yield (Greenblatt) % | -206.59 | |||||
| FCF Yield % | -105.95 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Valerio Therapeutics Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.443 | ||
| EPS (TTM) (€) | -0.153 | ||
| Beta | 2.77 | ||
| Volatility % | 40.12 | ||
| 14-Day RSI | 41.06 | ||
| 14-Day ATR (€) | 0.005726 | ||
| 20-Day SMA (€) | 0.11817 | ||
| 12-1 Month Momentum % | -62.11 | ||
| 52-Week Range (€) | 0.09 - 0.348 | ||
| Shares Outstanding (Mil) | 154.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Valerio Therapeutics Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Valerio Therapeutics Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Valerio Therapeutics Frequently Asked Questions
What is Valerio Therapeutics(XPAR:ALVIO)'s stock price today?
The current price of XPAR:ALVIO is €0.11. The 52 week high of XPAR:ALVIO is €0.35 and 52 week low is €0.09.
When is next earnings date of Valerio Therapeutics(XPAR:ALVIO)?
The next earnings date of Valerio Therapeutics(XPAR:ALVIO) is 2024-09-27 Est..
Does Valerio Therapeutics(XPAR:ALVIO) pay dividends? If so, how much?
Valerio Therapeutics(XPAR:ALVIO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers